Therefore, our working hypothesis is that inhibitors of CK-1δ able to modulate TDP-43 proteinopathy in vivo, may be a good therapeutic strategy for the severe ALS. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.